Oxybutynin

BRAND NAMES

• Ditropan 

• Ditropan XL (extended-release form) 

• Oxytrol (transdermal patch, also available OTC in some countries) 

• Gelnique (topical gel formulation)

MECHANISM OF ACTION

Oxybutynin is an antimuscarinic drug that blocks M3 muscarinic receptors in the detrusor muscle of the bladder. This reduces involuntary bladder contractions, increases bladder capacity, and helps control symptoms of urgency, frequency, and urge incontinence in overactive bladder.

PHARMACOKINETICS

Absorption 

Oxybutynin is well absorbed orally but undergoes significant first-pass metabolism, reducing bioavailability. Food may slightly delay absorption. Transdermal forms provide steadier absorption with less first-pass effect.

Distribution

Oxybutynin has a large volume of distribution, indicating extensive distribution into body tissues, including smooth muscle and the central nervous system. It is highly lipophilic and widely distributed beyond the bloodstream, which contributes to both its therapeutic effects and central anticholinergic side effects.

Metabolism 

Oxybutynin is extensively metabolized in the liver, mainly by CYP3A4 enzymes, into active and inactive metabolites, including N-desethyloxybutynin. It undergoes significant first-pass metabolism, which reduces its oral bioavailability and contributes to variability in response and side effects.

Elimination 

Oxybutynin and its metabolites are primarily eliminated through the kidneys in the urine. The elimination half-life is relatively short for the immediate-release form, while extended-release formulations provide more prolonged drug action.

PHARMACODYNAMICS

Oxybutynin is an antimuscarinic agent that blocks M3 receptors in the bladder detrusor muscle, reducing involuntary contractions and increasing bladder capacity. It also has mild antispasmodic and local anesthetic effects, which help decrease urgency, frequency, and urge incontinence in overactive bladder.

ADMINISTRATION

Oxybutynin is administered orally as immediate-release or extended-release tablets, or as a transdermal patch/gel. Oral forms are usually taken 2–3 times daily (IR) or once daily (ER), while patches are applied twice weekly and gel is applied daily to the skin. 

DOSAGE AND STRENGTH

Oxybutynin is available in immediate-release tablets (2.5 mg, 5 mg), extended-release tablets (5 mg, 10 mg, 15 mg), transdermal patches (3.9 mg/24 hours), and topical gel formulations (various strengths). The dose is individualized based on response and tolerability.

DRUG INTERACTIONS

Oxybutynin shows additive anticholinergic effects with other antimuscarinic drugs, increasing side effects like dry mouth and urinary retention. CYP3A4 inhibitors may increase its levels, while CNS depressants can enhance drowsiness and confusion.

FOOD INTERACTIONS

Oxybutynin can be taken with or without food, and food does not significantly affect its overall absorption. However, taking it with food may help reduce stomach irritation in some patients.

CONTRAINDICATIONS

Oxybutynin is contraindicated in patients with urinary or gastric retention, uncontrolled narrow-angle glaucoma, and hypersensitivity to the drug. It should also be avoided in patients with severe obstructive gastrointestinal disorders or myasthenia gravis.

SIDE EFFECTS

• Dry mouth 

• Constipation 

• Blurred vision 

• Dizziness 

• Drowsiness 

• Urinary retention 

• Tachycardia 

• Confusion (especially in elderly) 

• Heat intolerance / decreased sweating

OVER DOSE 

Overdose causes anticholinergic symptoms like dry mouth, flushing, fever, tachycardia, confusion, and urinary retention. Severe cases may lead to agitation, seizures, or coma, and treatment is mainly supportive in a hospital setting.

TOXICITY

Oxybutynin toxicity results from excessive anticholinergic effects, leading to dry mouth, hyperthermia, tachycardia, urinary retention, confusion, and hallucinations. In severe cases, it may progress to seizures, coma, or cardiovascular instability.